Companies Mentioned

Ranbaxy, Inc.

Category
Title
Summary
Date
Commentaries
Patent Law

The Federal Circuit has resolved prior inconsistencies in its case law and established a bright line rule to define infringement in product-by-process claims, holding that such infringement requires practice of the claimed process by the alleged infringer. In Abbott Labs v. Sandoz, 566 F.3d 1282 (Fed. Cir. 2009), the Federal…
Posted:
07/13/2009
Summaries
Patent Law >
New Settlements and Verdicts

The Lipitor patents involved in the settlement agreement are the basic compound patent, which expires in the United States in 2010; the enantiomer patent, which expires in the United States in 2011; as well as various process and crystalline form patents, which expire in 2016 and 2017; and the combination…
Date of ruling:
06/18/2008
The most advanced document                
         management system in the world.

Only $59 / person / month
FeaturesLawLoop Demo
FeaturesWelcome to the Future
Play LawLoop Demo